Paper Information

Title:  TREATMENT OF EXPERIMENTAL NEPHROTIC SYNDROM WITH ARTESUNATE
Type: SPEECH
Author(s): NOURI H.R.*,RAZAVI A.,MEHRABIAN F.,MIRSHAFIEI A.
 
 *DEP. OF IMMUNOLOGY, SCHOOL OF PUBLIC HEALTH, TEHRAN UNIVERSITY OF MEDICAL SCIENCES
 
Name of Seminar: IRANIAN CONGRESS OF PHYSIOLOGY AND PHARMACOLOGY
Type of Seminar:  CONGRESS
Sponsor:  PHYSIOLOGY AND PHARMACOLOGY SOCIETY, MASHHAD UNIVERSITY OF MEDICAL SCIENCE
Date:  2007Volume 18
 
 
Abstract: 

Introduction: This study was designed to test the therapeutic effect of a new antimalarial drug, artesunate in experimental model of nephritic syndrome.
Methods: To induce experimental nephrosis, Adriamycin was given once by a single intravenous injection. Six days latar, animals were treated by
intraperitoneal administration of artesunate. Therapeutic protocol was terminated on day 28 and animals were killed on day 49. The urine protein was measured by trichloroacetic acid method. The creatinine clearance was calculated by alkaline picrate method. Sodium and potassium concentrations were determined by flame photometry. Urine and blood urea nitrogen were assessed by the Veniamin method. Serum albumin was measured using the procedure of Doumas et al procedure. Evaluations of serum lipid levels were determined by the routine laboratory tests. Kidney specimens were processed using light microscopy. Renal tissues were fixed by immersion in 10% buffered formalin, embedded in paraffin, and 4-micron sections were stained with hematoxylin-eosin.
Results: Our results showed that treatment with Artesunate caused a significant reduction in the level of proteinuria, urine urea and urine sodium. In addition, decrease in serum triglyceride and increase in the level of serum albumin was significant. Moreover, treatment with Artesunate significantly reduced glomerular PMN and mononuclear cells infiltration, Hypercellularity, karyorrhexis, wire loops and hydropic change in capillary network. On the other hand, healthy controls receiving Artesunate showed a significant decrease in amounts of serum triglyceride, urine urea and urine sodium.
Conclusion: This study suggests that artesunate therapy can ameliorate proteinuria, and suppress the progression of glomerular lesions in experimental model of nephrotic syndrome and suggest that Artesunate can be use as a lipid lowering drug.

 
Keyword(s): 
 
Yearly Visit 5  
 
Latest on Blog
Enter SID Blog